Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Volagidemab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Volagidemab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Volagidemab. |
| Estrone | Estrone may increase the thrombogenic activities of Volagidemab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Volagidemab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Volagidemab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Volagidemab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Volagidemab. |
| Estriol | Estriol may increase the thrombogenic activities of Volagidemab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Volagidemab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Volagidemab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Volagidemab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Volagidemab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Volagidemab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Volagidemab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Volagidemab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Volagidemab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Volagidemab. |
| Equol | Equol may increase the thrombogenic activities of Volagidemab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Volagidemab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Volagidemab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Volagidemab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Volagidemab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Volagidemab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Volagidemab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Volagidemab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Volagidemab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Volagidemab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Volagidemab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Volagidemab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Volagidemab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Volagidemab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Volagidemab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Volagidemab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Volagidemab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Volagidemab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Volagidemab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Volagidemab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Volagidemab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Volagidemab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Volagidemab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Volagidemab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Volagidemab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Volagidemab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Volagidemab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Volagidemab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Volagidemab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Volagidemab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Volagidemab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Volagidemab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Volagidemab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Volagidemab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Volagidemab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Volagidemab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Volagidemab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Volagidemab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Volagidemab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Volagidemab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Volagidemab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Volagidemab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Volagidemab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Volagidemab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Volagidemab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Volagidemab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Volagidemab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Volagidemab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Volagidemab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Volagidemab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Volagidemab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Volagidemab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Volagidemab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Volagidemab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Volagidemab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Volagidemab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Volagidemab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Volagidemab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Volagidemab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Volagidemab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Volagidemab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Volagidemab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Volagidemab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Volagidemab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Volagidemab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Volagidemab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Volagidemab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Volagidemab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Volagidemab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Volagidemab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Volagidemab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Volagidemab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Volagidemab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Volagidemab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Volagidemab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Volagidemab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Volagidemab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Volagidemab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Volagidemab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Volagidemab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Volagidemab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Volagidemab. |